Evidence map›Paper›PMID 24926027›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2014

Modeling scenarios for the end of AIDS.

Viviane D Lima, Harsha Thirumurthy, James G Kahn, Jorge Saavedra, Carlos F Cárceres, Alan Whiteside

Open access · bronzeAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 3 countries.

Viviane D LimaBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Harsha ThirumurthyUniversity of North Carolina at Chapel Hill, NC.
James G KahnUniversity of California, San Francisco.
Jorge SaavedraAIDS Healthcare Foundation, Mexico City, DF.
Carlos F CárceresCayetano Heredia University, Peru, Miraflores, Lima.
Alan WhitesideCentre for International Governance Innovation, Waterloo, ON, Canada.
AIDS Healthcare Foundation · USAIDS Vancouver · CACentre for International Governance Innovation · CAUniversidad Peruana Cayetano Heredia · PEUniversity of California, San Francisco · USUniversity of North Carolina at Chapel Hill · US

Funding

Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Sheri Ann Lippman · 2001 to 2026
$57.4M
Research Services CoreP2CHD050924 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAREN B GUZZO · 2015 to 2026
$9.6M
Modeling different strategies to reduce the public health impact of the HCV/HIV eR03DA033851 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI LIMA, VIVIANE DIAS · 2012 to 2013
$55k
CIHR 125948-1CIHR 129971-1CIHR MOP-125948NICHD NIH HHS P2C HD050924NIDA NIH HHS R03 DA033851NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

At the end of 2012, 3 decades after the human immunodeficiency virus (HIV) was first identified, neither a cure nor a fully preventive vaccine was available. Despite multiple efforts, the epidemic remains an exceptional public health challenge. At the end of 2012, it was estimated that, globally, 35 million people were living with HIV, 2.3 million had become newly infected, and 1.6 million had died from AIDS-related causes. Despite substantial prevention efforts and increases in the number of individuals on highly active antiretroviral therapy (HAART), the epidemic burden continues to be high. Here, we provide a brief overview of the epidemiology of HIV transmission, the work that has been done to date regarding HIV modeling in different settings around the world, and how to finance the response to the HIV epidemic. In addition, we suggest discussion topics on how to move forward with the prevention agenda and highlight the role of treatment as prevention (TasP) in curbing the epidemic.

Indexed as

Models, TheoreticalAcquired Immunodeficiency SyndromeAntiretroviral Therapy, Highly ActiveHIV InfectionsHumansHIV epidemicmathematical modelspreventionTasPtreatment as prevention

Identifiers

PMID24926027
PMCPMC4141492
OpenAlexW2162838583

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.